New Inhaled Insulin Approved

June 30, 2014 3:58 PM

5 0

New Inhaled Insulin Approved

The FDA announced the approval of Afrezza (insulin human; MannKind Corporation) Inhalation Powder for the improvement of glycemic control in adults with diabetes mellitus. Afrezza Inhalation Powder is a rapid-acting inhaled insulin administered at the beginning of each meal or within 20 minutes of starting a meal. In patients with type 1 diabetes, Afrezza Inhalation Powder must be taken with a long-acting insulin.

The safety and efficacy of Afrezza were studied in 1,026 patients with type 1 diabetes and 1,991 patients with type 2 diabetes. The efficacy of mealtime Afrezza in type 1 diabetes patients was compared to mealtime insulin aspart, both in combination with basal insulin in a 24-week study. At Week 24,...

Read more

To category page